Anti-glycoprotein D antibody as well as preparation method and application thereof

By developing a variety of antibodies against HSV glycoprotein D, the problem of lack of effective antibodies in existing HSV infection treatment is solved, and a multifunctional treatment and detection scheme for HSV-1 and HSV-2 is provided, which improves the therapeutic effect and safety sex.

CN118922439APending Publication Date: 2024-11-08VIROGIN BIOTECH CANADA LTD +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380018496.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-26
Filing Date
2023-01-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of effective neutralizing and non-neutralizing antibodies in existing treatments for HSV infection is difficult to target the different biological and functional effects of HSV-1 and HSV-2, and traditional antiviral drugs may bring unexpected side effects .

Method used

A series of antibodies developed that can bind to different regions of the glycoprotein D (gD) protein of HSV, including heavy chain variable regions and framework regions, have specific binding capabilities and are able to bind to the gD protein in different affinity ranges, Provides neutralization or non-neutralization effects.

Benefits of technology

A variety of antibody toolkits are provided, which can target HSV-1 and HSV-2 infections, improve therapeutic effects, reduce side effects through specific binding and neutralization, and can be used to detect and treat HSV infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004960007600000091
    Figure BDA0004960007600000091
  • Figure BDA0004960007600000101
    Figure BDA0004960007600000101
  • Figure BDA0004960007600000201
    Figure BDA0004960007600000201
Patent Text Reader

Abstract

Provided herein are antibodies that bind to a gD protein. Also disclosed herein are compositions comprising an anti-gD protein antibody, pharmaceutical compositions comprising an anti-gD protein antibody and a pharmaceutically acceptable carrier. Also disclosed are polynucleotide sequences encoding anti-gD proteins, vectors comprising such polynucleotides, and cells capable of expressing anti-gD proteins. Also provided herein is a method for producing an antibody against gD protein, a method for treating an infection with HSV-1 and / or HSV-2, and a method for detecting HSV-1 and / or HSV-2.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 303,067, filed on January 26, 2022, the contents of which are incorporated herein by reference.

[0003] Sequence Listing

[0004] This application contains a sequence listing in the form of an XML file, entitled "157450002-00304WO.xml", with a size of 81,900 bytes, created on January 24, 2023. The contents contained in the sequence listing are incorporated herein by reference. Technical Field

[0005] The present invention relates to antibodies targeting glycoprotein D (gD) protein. Compositions, pharmaceutical compositions, polynucleotides, vectors and cells related to anti-gD protein antibodies are also disclosed. Methods for producing and using anti-gD protein antibodies are also provided. Background Art

[0006] Millions of people worldwide are exposed to the herpes simplex virus (HSV). HSV-1 infection is primarily associated with mild to severe symptoms, including blisters and inflammation of the cells of the mouth and eyes, but in some cases the infection can progress to more serious disease, including blindness, hearing loss, and fatal encephalitis. HSV-2 infection is widespread throughout the world and is almost exclusively sexually transmitted, causing genital herpes.

[0007] HSV has been explored for cancer therapy because it has several advantages as a template for viral oncolytic vectors (Carson et al., 2010). The relatively large genome of HSV enables it to accept multiple transgenes as large as 30 kb. Since the HSV genome does not integrate into the host genome, it generally does not cause mutations in its host. In addition, in some cases, oncolytic therapy can lead to infection with unintended pathogens, and the existence of a variety of antiviral drugs that are recognized as safe and effective provides a reassuring option for treating HSV infection.

[0008] Antibodies are widely used as therapeutic agents and as tools for developing new therapies. Antibodies against HSV are needed for the treatment of HSV infection, as well as for the development of tools to investigate the development of new therapies that utilize HSV-based oncolytic viruses. Both neutralizing and non-neutralizing HSV antibodies are needed. Summary of the invention

[0009] Antibodies that bind to the gD protein are provided herein. The various antibodies provided herein can bind to different regions of the gD protein, and therefore they may have different effects on the biology and function of this glycoprotein in the infectivity of HSV (e.g., HSV-1 or HSV-2). These antibodies include neutralizing antibodies and non-neutralizing antibodies, which form a toolbox for different applications to choose from.

[0010] In one aspect, provided herein is an antibody comprising a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs), designated CDR1, CDR2, and CDR3, wherein CDR1 is selected from SEQ ID NOs: 17-25, CDR2 is selected from SEQ ID NOs: 30-36, CDR3 is selected from SEQ ID NOs: 45-63, and wherein the antibody binds to the gD protein.

[0011] In some embodiments, the antibodies described herein include CDR1, CDR2, and CDR3, and CDR1, CDR2, and CDR3 include:

[0012] (a) SEQ ID NO: 17, SEQ ID NO: 30 and SEQ ID NO: 45, respectively;

[0013] (b) SEQ ID NO: 17, SEQ ID NO: 31 and SEQ ID NO: 46, respectively;

[0014] (c) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 47, respectively;

[0015] (d) SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0016] (e) SEQ ID NO: 20, SEQ ID NO: 33 and SEQ ID NO: 45, respectively;

[0017] (f) SEQ ID NO: 21, SEQ ID NO: 31 and SEQ ID NO: 49, respectively;

[0018] (g) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 50, respectively;

[0019] (h) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 51, respectively;

[0020] (i) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0021] (j) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 52, respectively;

[0022] (k) SEQ ID NO: 23, SEQ ID NO: 31 and SEQ ID NO: 53, respectively;

[0023] (l) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 54, respectively;

[0024] (m) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 55, respectively;

[0025] (n) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 56, respectively;

[0026] (o) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 57, respectively;

[0027] (p) are SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 58, respectively;

[0028] (q) are SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 59, respectively;

[0029] (r) SEQ ID NO: 17, SEQ ID NO: 34 and SEQ ID NO: 60, respectively;

[0030] (s) are SEQ ID NO: 24, SEQ ID NO: 35 and SEQ ID NO: 61, respectively;

[0031] (t) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 62, respectively; or

[0032] (u) are SEQ ID NO: 25, SEQ ID NO: 36 and SEQ ID NO: 63, respectively.

[0033] In some embodiments, the antibodies described herein include a framework region 1 (FR1) selected from SEQ ID NOs: 1-16, a framework region 2 (FR2) selected from SEQ ID NOs: 26-29, a framework region 3 (FR3) selected from SEQ ID NOs: 37-44, and a framework region 4 (FR4) selected from SEQ ID NOs: 64-66.

[0034] In some embodiments, the antibodies described herein include FR1, FR2, FR3, and FR4, and FR1, FR2, FR3, and FR4 include

[0035] (a) SEQ ID NO: 1, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0036] (b) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0037] (c) SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0038] (d) SEQ ID NO: 4, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0039] (e) SEQ ID NO: 5, SEQ ID NO: 27, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0040] (f) SEQ ID NO: 6, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0041] (g) SEQ ID NO: 7, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0042] (h) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0043] (i) SEQ ID NO: 9, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0044] (j) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 64, respectively;

[0045] (k) SEQ ID NO: 10, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0046] (l) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0047] (m) are SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0048] (n) are SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0049] (o) SEQ ID NO: 13, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0050] (p) are SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 42 and SEQ ID NO: 64, respectively;

[0051] (q) are SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0052] (r) SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0053] (s) are SEQ ID NO: 14, SEQ ID NO: 28, SEQ ID NO: 43 and SEQ ID NO: 66, respectively;

[0054] (t) SEQ ID NO: 15, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; or

[0055] (u) are SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 44 and SEQ ID NO: 64, respectively.

[0056] In some embodiments, the antibodies described herein include a heavy chain variable domain, wherein the heavy chain variable domain includes an amino acid sequence as shown in any one of SEQ ID NOs: 67-87. In some embodiments, the antibodies described herein include an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 67-87.

[0057] In some embodiments, the gD protein that specifically binds to the antibodies described herein is derived from a virus. In some embodiments, the virus is HSV. In some embodiments, the HSV is HSV-1 or HSV-2.

[0058] In some embodiments, the gD protein that specifically binds to the antibodies described herein is a recombinant gD protein.

[0059] In some embodiments, the antibodies described herein have a K ranging from about 1 pM to about 1 μM. D In some embodiments, K D The range of K is about 50 pM to about 4 nM. In some embodiments, K D The range of K is about 0.05 nM to 0.2 nM. In some embodiments, K D About 4 nM or less.

[0060] In some embodiments, the antibodies described herein are single domain antibodies (sdAbs). In some embodiments, the antibodies described herein are single heavy domain antibodies.

[0061] In some embodiments, the antibodies described herein are neutralizing antibodies. In some embodiments, the antibodies described herein are capable of neutralizing HSV-1 and / or HSV-2. In some embodiments, the neutralizing antibody comprises an amino acid sequence as set forth in SEQ ID NO: 85. In some embodiments, the neutralizing antibody comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 85.

[0062] In some embodiments, the antibodies described herein are multispecific antibodies. In some embodiments, the multispecific antibodies include the amino acid sequence shown in SEQ ID NO: 85 and one or more amino acid sequences selected from SEQ ID NO: 67-84 and 86-87.

[0063] In some embodiments, the antibodies described herein are non-neutralizing antibodies.

[0064] In another aspect, provided herein are compositions comprising the antibodies described herein. In some embodiments, provided herein are pharmaceutical compositions comprising the antibodies described herein and a pharmaceutically acceptable carrier.

[0065] In another aspect, provided herein are polynucleotides encoding the antibodies described herein.

[0066] In another aspect, provided herein is a vector comprising a polynucleotide as described herein.

[0067] In another aspect, provided herein is a cell capable of expressing an antibody as described herein. In another aspect, provided herein is a cell comprising a polynucleotide as described herein or a vector as described herein.

[0068] In another aspect, provided herein is a method of producing an antibody, comprising culturing the cell described herein and recovering the antibody from the cell.

[0069] In another aspect, provided herein is a method for treating HSV-1 and / or HSV-2 infection in a subject, comprising administering to the subject an effective amount of an antibody as described herein or a composition as described herein.

[0070] In another aspect, provided herein is a method for detecting HSV-1 and / or HSV-2 in a sample, comprising contacting the sample with an antibody described herein or a composition described herein, and detecting the presence of the antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0072] Figure 1 Results of serological response monitoring are provided. Comparison of raw ELISA data for pre-immune (Pre) and immune (d42) sera binding to inactivated HSV-1 ("E") and glycoprotein D ("G"). Total polyclonal responses (conventional and heavy chain IgG) were detected with anti-llama Fc IgG ( Figure 1 A), or hinge-specific mAb 1C10 to detect heavy chain IgG ( Figure 1 B).

[0073] Figure 2 The phage ELISA results of the phages extracted in the third round are provided. Figure 2 A shows a 96-well plate layout, Figure 2 B shows the A450 nm values ​​of specific round 3 clones. PBS: negative control; helper phage: positive control. DNA sequencing was performed on all clones, the sequences were analyzed, and certain VHHs were selected for soluble VHH expression and characterization.

[0074] Figure 3A provides the SEC profile of anti-glycoprotein D VHH. Figure 3 B provides the calibration results for the S200INCREASE column.

[0075] Figure 4 Results for immobilization of anti-human IgG are presented.

[0076] Figure 5 SPR sensorgrams showing high affinity binding of G44 VHH to fused glycoprotein D (referred to as "G-Fc") are provided. Kinetics and affinity were determined using single cycle kinetics by injecting G44 over a concentration range of 0.125 nM to 2 nM on the glycoprotein D-Fc surface.

[0077] Figure 6 SRP sensorgram results are provided, showing binding of sdAb to captured G-Fc.

[0078] Figure 7 A summary of SPR-based epitope binning results is provided. VHHs G19, G41, G44 and G77 bind to overlapping or competing epitopes on glycoprotein D. VHH G75 binds to an epitope that is non-overlapping or distinct from these other VHH groups.

[0079] Figure 8 SRP sensorgram results for epitope identification are provided. DETAILED DESCRIPTION

[0080] The disclosure and embodiments set forth herein are to be interpreted as exemplary only and not limiting the scope of the invention. Although specific terms are employed herein, unless otherwise indicated, they are used in a generic and descriptive sense only and not for purposes of limitation.

[0081] All publications, patents, and patent applications cited herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[0082] definition

[0083] In this article, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice of this article, preferred methods and materials are described herein. Therefore, the terms defined herein are more fully described by reference to the entire specification.

[0084] Unless otherwise defined, all technical and scientific terms, acronyms and abbreviations used herein have the same meaning as those commonly understood by those of ordinary skill in the art. Unless otherwise indicated, abbreviations and symbols for chemical and biochemical names conform to the IUPAC-IUB nomenclature. Unless otherwise indicated, all numerical ranges include the values ​​defining the range and all integer values ​​therebetween.

[0085] As used herein, the singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0086] The "and / or" used herein refers to and encompasses any and all possible combinations of one or more related listed items, and does not include combinations when interpreted with alternative expressions ("or"). In addition, it is also contemplated that in some embodiments of the present invention, any feature or combination of features set forth herein may be excluded or omitted.

[0087] Unless the context requires otherwise, the terms "comprise," "comprises," and "comprising" or similar terms are intended to refer to a non-exclusive inclusion, such that the described list of elements or features includes not only those stated or listed elements, but may also include other elements or features that are not listed or stated.

[0088] Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amine to carboxyl orientation, respectively.

[0089] It is to be understood that the present invention is not limited to the specific methodology, protocols, and reagents described as these may vary depending on the specific context in which they are used by one skilled in the art.

[0090] The term "about" as used herein will be understood by those of ordinary skill in the art and will vary to some extent depending on the specific context in which it is used. In some embodiments, the term "about" when referring to measurable values ​​such as amounts, time durations, etc. is intended to encompass variations acceptable in the art based on the standard error in making such measurements. In some embodiments, the term "about" when referring to such values ​​is intended to encompass differences of ±20% or ±10%, preferably ±5%, more preferably ±1%, and even more preferably ±0.1% from the specified value, as such differences are appropriate for practicing the disclosed methods.

[0091] As used herein, the terms "percent identity" and "% identity" as applied to nucleic acid or polynucleotide sequences refer to the percentage of residue matches between at least two nucleic acid or polynucleotide sequences compared using a standardized algorithm. Such an algorithm can insert gaps in the compared sequences in a standardized and repeatable manner to optimize the comparison between the two sequences, and thus achieve a more meaningful comparison of the two sequences.

[0092] The percent identity between nucleic acid or polynucleotide sequences can be determined using a commonly used and freely available set of sequence comparison algorithms provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, SF et al. (1990) J. Mol. Biol. 215:403-410) (available from several sources, including NCBI in Bethesda, Maryland and at http: / / www.ncbi.nlm.nih.gov / BLAST / ).

[0093] Due to the degeneracy of the genetic code, nucleic acid or polynucleotide sequences that do not show a high degree of identity can still encode similar amino acid sequences. It should be understood that this degeneracy can be used to make changes in nucleic acid sequences to generate multiple nucleic acid sequences that all encode substantially the same protein. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and / or deoxyinosine residues (Batzer et al., (1991) Nucleic Acid Res 19:5081; Ohtsuka et al. (1985) J Biol Chem 260:2605-2608; Cassol et al. (1992); Rossolini et al. (1994) Mol Cell Probes 8:91-98). The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. The term nucleic acid can be used interchangeably with polynucleotides and (where appropriate) genes, cDNAs, and mRNAs encoded by genes.

[0094] As used herein, "percentage (%) of amino acid sequence identity" with respect to a peptide, polypeptide or protein sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in another peptide or polypeptide sequence, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity, and without considering any conservative substitutions as part of the sequence identity. The percentage of amino acid sequence identity herein is measured using BLAST software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the compared sequences.

[0095] Amino acid substitution refers to the replacement of one amino acid in a polypeptide with another amino acid. Exemplary substitutions are shown in Table 1. Amino acid substitutions can be introduced into a protein of interest and the products screened for the desired activity, e.g., maintained / improved biological activity.

[0096]

[0097]

[0098] Amino acids can be grouped according to common side chain properties:

[0099] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;

[0100] (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0101] (3) Acidic: Asp, Glu;

[0102] (4) Basic: His, Lys, Arg;

[0103] (5) Residues that affect chain orientation: Gly, Pro;

[0104] (6) Aromatic: Trp, Tyr, Phe.

[0105] Non-conservative substitutions will necessarily replace a member of one of these categories with another category. The term "corresponding to" with respect to a nucleotide or amino acid position of a sequence such as listed in the sequence table refers to a nucleotide or amino acid position identified after alignment with a target sequence based on a structural sequence alignment or using a standard alignment algorithm (such as the GAP algorithm). For example, the corresponding residues of similar sequences (such as fragments or species variants) can be determined by alignment with a reference sequence using a structural alignment method. By comparing sequences, those skilled in the art can, for example, use conservative and identical amino acid residues as a guide to identify corresponding residues.

[0106] As used herein, the term "wild type" refers to naturally occurring.

[0107] As used herein, the terms "range," "ranges," or "ranging" mean that the numerical value in question is equal to or above the minimum value of the range provided and equal to or below the maximum value of the range provided.

[0108] As used herein, "antibody" refers to any immunoglobulin (Ig) molecule, including but not limited to monoclonal antibodies, human antibodies, non-human antibodies, llama antibodies, humanized antibodies, chimeric antibodies, single domain antibodies, antibody fragments, antigen-binding fragments, bispecific antibodies, multispecific antibodies, multimeric antibodies, single chain antibodies, or any functional fragment, mutant, variant or derivative thereof, which specifically binds to or interacts with at least one specific antigen (e.g., HSV-1gD protein, HSV-2gD protein).

[0109] In humans and most mammals, the antibody unit is typically composed of four polypeptide chains: two identical heavy chains connected by disulfide bonds and two identical light chains. The light chain consists of a variable domain VL and a constant domain CL, while the heavy chain contains a variable domain VH and three to four constant domains, such as CH1, CH2, and CH3. Based on the amino acid sequence of the heavy chain constant domain, immunoglobulins can be divided into five major categories, namely IgA, IgD, IgE, IgG, and IgM. IgA and IgG are typically further subdivided into IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4. The light chains of vertebrate antibodies can be classified into one of two different types based on the amino acid sequence of their constant domains, namely kappa (κ) and lambda (λ).

[0110] As used herein, "antigen-binding fragment" or "antibody fragment" refers to a portion of an immunoglobulin molecule that retains a heavy chain and / or light chain antigen-binding site, such as a heavy chain complementary determining region, a light chain complementary determining region, a heavy chain variable region (VH) or a light chain variable region (VL). Antibody fragments include, but are not limited to, Fab fragments (monovalent fragments consisting of VL or VH), F(ab)2 fragments (bivalent fragments comprising two Fab fragments connected by a disulfide bridge in the hinge region), Fd fragments consisting of VH and CH1 domains, Fv fragments consisting of the VL and VH domains of a single arm of an antibody, dAb fragments consisting of a VH domain, or variable domains (VHH) from, for example, human or camelid sources. These antibody fragments can be obtained using well-known techniques. VHH refers to an antigen-binding fragment of a heavy chain antibody only.

[0111] The antibody variable domain is composed of a "framework" (FR) region and a "complementarity determining region" (CDR). For example, in some embodiments, the heavy chain variable domain of an antibody has a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0112] CDR sequences are variable antibody sequences that respond to specificity, duration and intensity to recognize and bind to antigenic epitopes. FR sequences are the remaining sequences of the variable regions except those sequences defined as CDRs. CDR represents the complementary determining regions as defined by at least one recognition mode by those skilled in the art. The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography", J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Dev Comp Immunol, 2003 Jan;27(1):55-77 (“IMGT” numbering scheme); Honegger A and Plückthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool”, J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme); and Martin et al., “Modeling antibody hypervariable loops: a combined algorithm (Modeling Antibody Hypervariable Loops: A Combinatorial Algorithm), PNAS, 1989, 86(23):9268-9272, ("AbM" numbering scheme). For example, in some embodiments, the CDRs in the present application are determined based on the IMGT numbering scheme.

[0113] The boundary of given CDR or FR can change according to the scheme for identification.For example, the Kabat scheme is based on structural alignment, and the Chothia scheme is based on structural information.The numbering of Kabat and Chothia schemes is based on the most common antibody region sequence length, with insertion letter mark insertion, for example "30a", and disappearance occurs in some antibodies.These two schemes place some insertions and deletions (" indels ") in different positions, resulting in different numbering.The Contact scheme is based on the analysis of complex crystal structure, and is similar to the Chothia numbering scheme in many aspects.The AbM scheme is a compromise between the Kabat and Chothia definitions used by the AbM antibody modeling software based on Oxford Molecular.In some embodiments, CDR can be defined according to any one of the combination, AbM definition and / or contact definition of Chothia numbering scheme, Kabat numbering scheme, IMGT numbering scheme, Kabat, IMGT and Chothia.

[0114] As used herein, "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., a receptor) and its binding partner (e.g., a ligand). The affinity of a molecule and its partner can generally be expressed by the equilibrium dissociation constant (K D )(or its inverse equilibrium association constant K A ). Affinity can be measured by common methods known in the art, including those described herein. See, for example, Pope ME, Soste MV, Eyford BA, Anderson NL, Pearson TW, (2009) J. Immunol. Methods, 341(1-2):86-96 and the methods described therein.

[0115] The term "specific binding" or "binding" to a specific antigen as used herein refers to a binding that is measurably different from non-specific interactions. For example, in some embodiments, a binding molecule (e.g., a single domain antibody) specifically binds to a target molecule (e.g., an antigen) when the binding molecule reacts or associates more frequently, more rapidly, and / or with a higher affinity (compared to the affinity of the binding molecule and the surrogate molecule) for a longer duration. If a binding molecule (e.g., sdAb) binds to a target molecule more easily and / or with a longer duration than it binds to other molecules, the binding molecule "specifically binds" to the target molecule. It should be understood that a binding molecule (e.g., sdAb) that specifically binds to a first target may specifically bind or non-specifically bind to a second target. Like this, "specific binding" does not necessarily require (although it may include) exclusive binding. In some embodiments, specific binding can be determined, for example, by comparing binding to a specific antibody with binding to an antibody that is not bound to a specific antigen. For example, when an antibody has at least about 10 -4 M, at least about 10 -5 M, at least about 10 -6 M, at least about 10 -7 M, at least about 10 - 8 M, at least about 10 -9 M, at least about 10 -10 M, at least about 10 -11 M, at least about 10 -12 M or higher K D When K D Refers to the off-rate of an antibody / antigen interaction. In some embodiments, an antibody that specifically binds to an antigen will have a K that is lower than that of an antibody that does not bind to the same antigen.D K that is 20, 50, 100, 500, 1000, 5000, 10000 or more times greater D In some embodiments, binding between an antibody and a specific antigen can be demonstrated by an EC50 value, determined using any suitable method known in the art, including, for example, flow cytometry.

[0116] As used herein, "epitope" refers to the portion of an antigen that is recognized and bound by an antibody. An antigen may have more than one epitope recognized by an antibody.

[0117] As used herein, "composition" refers to any mixture of two or more products, substances or compounds, including but not limited to proteins, antibodies, polynucleotides, vectors or cells. It can be a solution, suspension, liquid, powder, paste, aqueous, non-aqueous or any combination thereof.

[0118] As used herein, "pharmaceutical composition" refers to an active agent formulated into a pharmaceutically acceptable or physiologically acceptable solution for administration to cells or animals alone or in combination with one or more other therapeutic forms. It should also be understood that the compositions herein can be administered in combination with other agents (e.g., cytokines, growth factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies, or other various pharmaceutically active agents) if desired. There is virtually no restriction on other ingredients that may also be included in the composition, as long as the additional agent does not adversely affect the ability of the composition to deliver the intended therapy. Some non-limiting examples of ingredients that may be included in the composition are carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. Pharmaceutical compositions facilitate administration of antibodies or cells described herein to subjects. There are a variety of administration techniques in the art, including but not limited to intravenous, oral, aerosol, parenteral, ocular, pulmonary, and topical administration.

[0119] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not abrogate the biological activity or properties of the therapeutic compound and is relatively nontoxic, i.e., the material can be administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with any component of a composition containing the material. Pharmaceutically acceptable ingredients include compounds, materials, compositions, and / or dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0120] As used herein, "effective amount" refers to an amount of a pharmaceutical composition sufficient to significantly and actively alleviate the symptoms and / or conditions to be treated (e.g., provide a positive clinical response). The effective amount of a pharmaceutical composition will vary with the specific condition being treated, the severity of the condition, the duration of treatment, the nature of concurrent treatments, the specific composition employed, the carrier and / or specific pharmaceutically acceptable excipients used, and the knowledge and expertise of the attending physician and similar factors.

[0121] As used herein, "disease" or "disorder" refers to a condition that requires and / or desires treatment.

[0122] The terms "treat", "treating" or "treatment" as used herein refer to improving a disease or condition, such as slowing down or stopping or reducing the development of a disease or condition, or reducing the clinical symptoms of at least one disease or condition. For example, in some embodiments, improving a disease or condition may include obtaining a beneficial or desired clinical result, which includes, but is not limited to, any one or more of the following: alleviating one or more symptoms, reducing the extent of the disease, preventing or delaying the spread of the disease, preventing or delaying the recurrence of the disease, delaying or slowing the progression of the disease, improving the disease state, inhibiting the disease or the progression of the disease, inhibiting or slowing the disease or its deterioration, preventing its development and alleviating (whether partially or completely).

[0123] The terms "individual" and "subject" used herein are used interchangeably herein to refer to animals. For example, in some embodiments, the animal is a mammal. In some embodiments, the animal is a human, a rodent, anthropoid ape, a feline, a canine, an equine, a bovine, a pig, a sheep, a goat, a mammalian laboratory animal, a mammalian farm animal, a mammalian sports animal, or a mammalian pet. The animal can be male or female, and can be at any suitable age, including infants, teenagers, adolescents, adults, and the elderly. In some examples, "individual" or "subject" refers to an animal that needs to be treated for a disease or condition. In some embodiments, the animal being treated can be a "patient", indicating the fact that the animal has been identified as suffering from a condition associated with treatment, or is at sufficient risk of contracting the condition. In a specific embodiment, the animal is a human, such as a human patient.

[0124] HSV and gD protein

[0125] Herpes simplex virus (HSV, also known as HHV) is generally divided into two types: HSV-1 and HSV-2. HSV belongs to the family Herpesviridae and is divided into three subfamilies: α-herpesvirus, β-herpesvirus and γ-herpesvirus. HSV belongs to the α-herpesvirus subfamily and generally has a short replication cycle and can infect a wide range of hosts. Mature HSV includes the following characteristics: 1) ~152kb of linear double-stranded DNA, which encodes at least 74 genes, 2) encapsidated in an icosahedral shell composed of 162 capsid particles, which are composed of six different viral proteins, 3) surrounded by 20-23 different viral envelope proteins with structural and regulatory functions, and 4) covered by an envelope with at least 13 different glycoproteins (with different shapes and sizes), different glycoproteins such as gB, gD, gH, gL, some of which are incorporated into mature virions. Among these viral glycoproteins, four (gB, gD and the heterodimeric gH / gL) are involved in HSV fusion and entry.

[0126] The wild-type mature HSV-1gD protein is a type I membrane glycoprotein with a length of 369 amino acid residues and a length of about 8-10 nm. HSV-1gD expresses the amino acid sequence of the wild-type HSV-1gD protein with a signal peptide of 25 amino acids in length as shown in SEQ ID NO: 88 (UniProtKB-Q69091 (GD_HHV11)).

[0127] SEQ ID NO:88 (wild-type HSV-1 gD protein):

[0128] MGGAAARLGAVILFVVIVGLHGVRSKYALVDASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLPDPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVMEYTECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKIND WTEITQFILEHRAKGSCKYALPLRIPPSACLSPQAYQQGVTVDSIGLMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPPELSETPNATQPELAPEDPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNNMGLIAGAVGGSLLAALVICGIVYWMRRHTQKAPKRIRLPHIREDDQPSSHQPLFY

[0129] Wild-type mature HSV-2gD protein is a one-way I-type membrane glycoprotein with a length of 363 amino acid residues.HSV-2gD is expressed with a signal peptide of 30 amino acids in length.The amino acid sequence of wild-type HSV-2gD protein is shown in SEQ ID NO:89 (UniProtKB-P03172 (GD_HHV23)).

[0130] SEQ ID NO:89 (wild-type HSV-2 gD protein):

[0131] MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDRLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKIN DWTEITQFILEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGLMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY

[0132] HSV gD protein is irregularly aggregated on the surface of the viral membrane. HSV gD is typically organized into an extracellular domain, a transmembrane domain and a short cytoplasmic tail. According to crystallographic studies, the gD extracellular domain has an immunoglobulin-like core with N and C-terminal extensions at both ends. The N-terminal domain is called the receptor binding domain (RBD), and this part of gD binds to specific host receptors. The C-terminal domain is called the pro-fusion domain (PFD), which interacts with gH / gL and gB.

[0133] Antibody

[0134] Provided herein are novel antibodies that specifically bind to the gD protein.

[0135] In one aspect, provided herein is an antibody comprising a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs) designated as CDR1, CDR2, and CDR3, wherein CDR1 is selected from the group consisting of SEQ ID NOs: 17-25, CDR2 is selected from the group consisting of SEQ ID NOs: 30-36, CDR3 is selected from the group consisting of SEQ ID NOs: 45-63, and wherein the antibody binds to a gD protein.

[0136] As used herein, "gD protein" or "glycoprotein D" includes wild-type gD proteins of all isotypes, functional variants of wild-type gD proteins, precursors of gD proteins, recombinant gD proteins, synthetic gD proteins, purified gD proteins, isolated gD proteins, gD proteins fused to another protein, gD proteins joined to another entity (e.g., a tag), truncated forms of any gD protein, or functional fragments of any gD protein. Wild-type gD proteins from different HSV strains or clones may also have sequence differences, such as having slightly different amino acid sequences. For example, in some embodiments, the gD protein is as described in UniProtKB-P03172 (GD_HHV23), UniProtKB-Q991M3 (Q991M3_HHV1), or UniProtKB-Q69091 (GD_HHV11). In some embodiments, the gD protein used herein includes an amino acid sequence that is at least 80%, 85%, 90%, 95%, 98% or 99% identical to any one of SEQ ID NOs: 88 and 89. In some embodiments, the fragment can consist of at least 10-20 amino acids, at least 20-30 amino acids, at least 30-50 amino acids, or all amino acids of the native sequence, or can be otherwise recognizable to one of ordinary skill in the art as being derived from the native sequence.

[0137] In some embodiments, the antibodies described herein include any suitable framework region (FR) sequence, as long as the antibody can specifically bind to HSV-1 gD protein.

[0138] In some embodiments, the antibodies described herein include CDR1, CDR2, and CDR3, wherein CDR1, CDR2, and CDR3 include

[0139] (a) SEQ ID NO: 17, SEQ ID NO: 30 and SEQ ID NO: 45, respectively;

[0140] (b) SEQ ID NO: 17, SEQ ID NO: 31 and SEQ ID NO: 46, respectively;

[0141] (c) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 47, respectively;

[0142] (d) SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0143] (e) SEQ ID NO:20, SEQ ID NO:33 and SEQ ID NO:45, respectively;

[0144] (f) SEQ ID NO:21, SEQ ID NO:31 and SEQ ID NO:49, respectively;

[0145] (g) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 50, respectively;

[0146] (h) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 51, respectively;

[0147] (i) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0148] (j) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 52, respectively;

[0149] (k) SEQ ID NO: 23, SEQ ID NO: 31 and SEQ ID NO: 53, respectively;

[0150] (l) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 54, respectively;

[0151] (m) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 55, respectively;

[0152] (n) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 56, respectively;

[0153] (o) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 57, respectively;

[0154] (p) are SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 58, respectively;

[0155] (q) are SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 59, respectively;

[0156] (r) SEQ ID NO: 17, SEQ ID NO: 34 and SEQ ID NO: 60, respectively;

[0157] (s) are SEQ ID NO: 24, SEQ ID NO: 35 and SEQ ID NO: 61, respectively;

[0158] (t) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 62, respectively; or

[0159] (u) are SEQ ID NO: 25, SEQ ID NO: 36 and SEQ ID NO: 63, respectively.

[0160] In some embodiments, the antibodies described herein include a framework region 1 (FR1) selected from SEQ ID NOs: 1-16, a framework region 2 (FR2) selected from SEQ ID NOs: 26-29, a framework region 3 (FR3) selected from SEQ ID NOs: 37-44, and a framework region 4 (FR4) selected from SEQ IDs: 64-66.

[0161] In some embodiments, the antibodies described herein include FR1, FR2, FR3, and FR4, and FR1, FR2, FR3, and FR4 include

[0162] (a) SEQ ID NO: 1, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0163] (b) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0164] (c) SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0165] (d) SEQ ID NO: 4, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0166] (e) SEQ ID NO: 5, SEQ ID NO: 27, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0167] (f) SEQ ID NO: 6, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0168] (g) SEQ ID NO: 7, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0169] (h) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0170] (i) SEQ ID NO: 9, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0171] (j) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 64, respectively;

[0172] (k) SEQ ID NO: 10, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0173] (l) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0174] (m) are SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0175] (n) are SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0176] (o) SEQ ID NO: 13, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0177] (p) are SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 42 and SEQ ID NO: 64, respectively;

[0178] (q) are SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0179] (r) SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0180] (s) are SEQ ID NO: 14, SEQ ID NO: 28, SEQ ID NO: 43 and SEQ ID NO: 66, respectively;

[0181] (t) SEQ ID NO: 15, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; or

[0182] (u) are SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 44 and SEQ ID NO: 64, respectively.

[0183] The amino acid sequences of SEQ ID NOs: 1-66 are shown below.

[0184]

[0185]

[0186] For the purposes of this application, CDR1, CDR2 and CDR3 are in the antibodies described herein in the direction from N-terminus to C-terminus. FR1 is located at the N-terminus of the antibodies described herein, FR2 is located between CDR1 and CDR2, FR3 is located between CDR2 and CDR3, and FR4 is located at the C-terminus of the antibodies described herein.

[0187] In some embodiments, the antibodies described herein include a heavy chain variable region, wherein the heavy chain variable region includes an amino acid sequence as shown in any one of SEQ ID NOs: 67-87. In some embodiments, the antibodies described herein include an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 67-87 (Table 3). Preferably, the sequence variation does not significantly reduce the ability of the antibody to bind to the gD protein, or the sequence variation does not prevent the antibody from specifically binding to the gD protein. In some embodiments, the sequence variation does not increase the K of the antibody described herein to bind to the gD protein. D In some embodiments, the sequence variation does not increase the K value of the antibodies described herein for binding to the gD protein. D The value may be increased by more than 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% or 50%. In some embodiments, at least part of the sequence variation may occur through conservative amino acid substitutions.

[0188]

[0189]

[0190] In some embodiments, the antibodies described herein may include one (monovalent) or multiple (multivalent) heavy chain variable regions (VHH). In some embodiments, the antibodies described herein include multiple, for example two, three or four VHHs, which are optionally connected by one or more linkers. In some embodiments, the antibodies described herein include two VHHs, which are optionally connected by a linker. In some embodiments, each of the two VHHs has a sequence as shown in any one of SEQ ID NOs: 67-87.

[0191] In some embodiments, the antibodies described herein are multispecific antibodies, such as bispecific antibodies, which include one or more VHHs disclosed herein. For example, a multispecific antibody may include a VHH selected from the sequence shown in SEQ ID NO: 67-87, and another binding portion (e.g., a variable region) that binds to another epitope or antigen. As another example, a multispecific antibody may include two or more VHHs selected from the sequence shown in SEQ ID NO: 67-87, and another binding portion (e.g., a variable region) that binds to another epitope or antigen, wherein the two or more VHHs may be the same or different, optionally connected by one or more linkers. In some embodiments, a multispecific antibody includes the amino acid sequence shown in SEQ ID NO: 85, and one or more amino acid sequences selected from SEQ ID NO: 67-84 and 86-87.

[0192] In some embodiments, the gD protein to which the antibodies described herein specifically bind is derived from a virus. In some embodiments, the virus is any virus that expresses the gD protein. In some embodiments, the virus is HSV. In some embodiments, the HSV is HSV-1 or HSV-2.

[0193] The terms "gD protein derived from HSV", "gD protein from HSV source" or "HSV gD protein" used herein refer to the origin or source of the gD protein being HSV, which may include wild-type HSV gD protein, recombinant HSV gD protein, synthetic HSV gD protein, purified HSV gD protein, isolated HSV gD protein, HSV gD protein fused to another protein, HSV gD protein conjugated to a tag, or a fragment thereof. In some embodiments, the fragment comprises the extracellular domain of the HSV gD protein or a portion thereof.

[0194] In some embodiments, the gD protein specifically bound by the antibodies described herein is a recombinant gD protein. Recombinant protein as used herein refers to a protein encoded by recombinant DNA. Recombinant DNA is a section of DNA produced by combining at least two fragments from two different sources. Modification of genes by recombinant DNA technology can lead to the expression of mutant proteins. Recombinant proteins are obtained by cloning the recombinant DNA encoding the protein into a system (i.e., expression system) that supports gene expression and RNA translation. It should be understood that a technician can select a suitable expression system and conditions for recombinant DNA expression. Some non-limiting examples of expression systems are mammalian expression systems, bacterial expression systems, yeast expression systems, and insect expression systems. In some embodiments, recombinant HSV-1 gD protein includes HSV-1 gD and Fc region or Fc fragment.

[0195] In some embodiments, the antibodies described herein bind to HSV-1 and / or HSV-2. In some embodiments, the antibodies described herein bind to HSV-1 and / or HSV-2 by targeting the gD protein on the surface of HSV-1 and / or HSV-2.

[0196] In some embodiments, the antibodies described herein have a K ranging from about 1 pM to about 1 μM. D In some embodiments, K D The range of K is about 50 pM to about 4 nM. In some embodiments, K D The range of K is about 0.05 nM to 0.2 nM. In some embodiments, K D About 4 nM or less.

[0197] K D Refers to the dissociation rate of an antibody / antigen interaction. Affinity is the strength with which a single molecule binds to its ligand. It is typically expressed by the equilibrium dissociation constant (K D ) is measured and reported, and this constant is used to evaluate and rank the order strength of bimolecular interactions. The binding of an antibody to its antigen is a reversible process, and the rate of the binding reaction is proportional to the concentration of the reactants. At equilibrium, the rate of formation of the [antibody][antigen] antibody / antigen complex is equal to the rate of dissociation into its components. K D is inversely proportional to affinity, so K D The smaller the value, the greater the affinity of the antibody for its target. Because monoclonal antibodies are selective only for the same epitope, affinity determination of monoclonal antibodies can be performed with high precision. But in the case of polyclonal antibodies, only an average affinity can be obtained because polyclonal antibodies detect epitopes that are heterogeneous and have a mixture of different antibody / antigen complexes. For monoclonal antibodies, K is calculated as follows D :K D=[antibody][antigen] / [antibody / antigen complex], where [X] refers to the concentration of X. Methods for determining antibody affinity include, but are not limited to, ELISA-based methods and other biophysical methods (e.g., microscale thermophoresis (MST) and surface plasmon resonance (SPR)). Preferably, SPR is used to measure the K of binding between the antibodies described herein and the gD protein. D More information on SPR and its operating procedures can be found in Surface Plasmon Resonance, Nico J. Mol Marcel JE Fascher, DOI: 10.1007 / 978-1-60761-670-2 ISBN: 978-1-60761-669-6.

[0198] In some embodiments, the various antibodies described herein bind to different epitopes on the gD protein and therefore, in some embodiments, may have different effects on the biology and function of this glycoprotein in the infectivity of HSV-1 and / or HSV-2.

[0199] In some embodiments, the antibodies described herein are single domain antibodies (sdAb). In some embodiments, the antibodies described herein are single heavy domain antibodies. "Single domain antibodies" (sdAb) used herein refers to antibodies consisting of a single variable domain of an IgG antibody. For example, in some embodiments, a single domain antibody is a single heavy chain domain antibody or VHH antibody, which consists of a single variable domain of a heavy chain IgG (hcIgG) molecule produced by camelid mammals (e.g., llamas, camels, and alpacas).

[0200] In some embodiments, the antibodies described herein are neutralizing antibodies. In some embodiments, the antibodies described herein are capable of neutralizing HSV-1 and / or HSV-2. In some embodiments, the neutralizing antibody has an amino acid sequence as shown in SEQ ID NO: 85. In some embodiments, the neutralizing antibody has an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 85. Preferably, the sequence variation does not significantly reduce the ability of the antibody to bind to the gD protein, or the sequence variation does not prevent the antibody from specifically binding to the gD protein. In some embodiments, the sequence variation does not increase the K of the antibodies described herein binding to the gD protein. D In some embodiments, the sequence variation does not increase the K value of the binding between the antibodies described herein and the gD protein. D The value may be increased by more than 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40% or 50%. In some embodiments, at least part of the sequence variation may occur through conservative amino acid substitutions.

[0201] Neutralizing antibodies (NAbs) are antibodies that protect cells from pathogens or infectious particles (such as HSV-1 or HSV-2) by biologically neutralizing any effects they have. Neutralization renders the particle no longer infectious or pathogenic. Neutralizing antibodies can inhibit infectivity by binding to the pathogen and blocking the molecules required for cell entry. In some embodiments, neutralizing antibodies can neutralize the biological effects of an antigen without the need for immune cells. Neutralization assays can be performed and measured in different ways, including but not limited to using techniques such as plaque reduction assays (which compare viral plaque counts in control wells to those in inoculated cultures), microneutralization assays performed in microtiter plates filled with small amounts of serum, or colorimetric assays that rely on biomarkers that indicate inhibition of viral metabolism (Kaslow, RA; Stanberry, LR; Le Duc, JW, eds. (2014). Viral Infections of Humans: Epidemiology and Control (5th ed.). Springer. p. 56. ISBN 9781489974488).

[0202] In some embodiments, the antibodies described herein are non-neutralizing antibodies. Non-neutralizing antibodies specifically bind to pathogens but do not interfere with the infectivity of pathogens. This may be because the non-neutralizing antibodies do not bind to the correct area. Non-neutralizing antibodies may be important for marking particles of immune cells, indicating that they have been targeted, after which the particles are processed and ultimately destroyed by the recruited immune cells.

[0203] In some embodiments, the antibodies described herein are humanized or partially humanized. "Humanized" or "humanization" as used herein means modifying the amino acid sequence of the antibodies described herein to reduce their immunogenicity in humans. Humanization is usually achieved by modifying the sequence of the antibody to increase its similarity to its naturally occurring counterpart in humans. Two main methods have been used to convert murine antibodies into humanized antibodies: rational design and empirical methods. The rational design method is characterized by antibody structure modeling, generating some variants of the engineered antibody and evaluating their binding or any other properties of interest. If the designed variant does not produce the expected results, a new design and combination evaluation cycle is initiated. Rational design methods include, but are not limited to, complementary determining region (CDR) transplantation, surface remodeling, superhumanization, and human string content optimization, among which CDR transplantation is the most widely used. The humanized antibody produced by CDR transplantation comprises amino acids from the six CDRs of the parent murine mAb, which are transplanted onto the human antibody framework. Low levels of non-human sequences (~5%) in humanized antibodies have been shown to be effective in reducing immunogenicity and prolonging human serum half-life (7).

[0204] Simple transplantation of CDR sequences usually produces humanized antibodies that are weaker than the parental murine mAb in binding to the antigen, and it has been reported that the affinity is reduced by up to hundreds of times (Eigenbrot et al., 1994, Proteins 18, 49-62). In order to restore high affinity, the antibody must be further designed to fine-tune the structure of the antigen binding loop. This is usually achieved by replacing the key residues in the framework region of the antibody variable domain with matching sequences from the parental murine antibody. These framework residues are generally related to the structure of the CDR loop, although some framework residues themselves may directly contact the antigen (Mian et al., 1991, J Mol Biol 217, 133-151). It is already clear that the realization of antibody humanization by a reasonable method faces a higher uncertainty. In addition, due to reliance on structural biology that is not easily available to many laboratories, the widespread use of this technology has also been limited.

[0205] In contrast to the rational design method, the empirical method does not require structural information of the antibody. These methods rely on the generation of large combinatorial libraries and the selection of desired variants by enrichment techniques such as phage, ribosome or yeast display or by high throughput screening techniques. These methods rely on selection rather than assuming the impact of mutations on antibody structure. These methods include but are not limited to framework libraries, guide selection, framework shuffling and human engineering. However, the success of these methods mainly depends on the construction of large libraries, because high affinity antibodies can be isolated from large antibody repertoires.

[0206] In some embodiments, the antibodies described herein are conjugated to a label or drug moiety (eg, a toxin).

[0207] Composition

[0208] In another aspect, provided herein are compositions comprising an antibody described herein.

[0209] In another aspect, provided herein is a pharmaceutical composition comprising an antibody described herein and a pharmaceutically acceptable carrier.

[0210] The compositions or pharmaceutical compositions described herein may include a pharmaceutically acceptable carrier, diluent or excipient. "Pharmaceutically acceptable carriers, diluents or excipients" as used herein include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, surfactant or emulsifier approved by the U.S. Food and Drug Administration as acceptable for use in humans or livestock. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter; waxes; animal fats and vegetable fats; paraffins; silicones; bentonite; silicic acid; zinc oxide; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, soybean oil, etc.; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; alcohol; phosphate buffered saline; and any other compatible substances used in pharmaceutical formulations.

[0211] Liquid pharmaceutical compositions (whether they are solutions, suspensions or other similar forms) may include one or more of the following: sterile diluents, such as water for injection, saline solutions, preferably physiological saline; Ringer's solution; isotonic sodium chloride; fixed oils, such as synthetic monoglycerides or diglycerides, which can be used as solvents or suspension media; polyethylene glycol; glycerol; propylene glycol or other solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite, etc.; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates; and agents for adjusting tonicity, such as sodium chloride or dextrose. Parenteral preparations can be packaged in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Injectable pharmaceutical compositions are preferably sterile.

[0212] The compositions may be suitably developed for intravenous, intratumoral, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, ocular or other routes of administration.

[0213] Polynucleotide

[0214] On the other hand, the present invention provides polynucleotides encoding antibodies described herein. The polynucleotide sequences encoding antibodies described herein can be operably linked to one or more regulatory components, such as promoters and enhancers, which enable the nucleotide sequence to be expressed in a specified host cell. The polynucleotides can be cDNAs. The polynucleotides described herein are obtained by methods readily available in the art.

[0215] Carrier

[0216] On the other hand, the present invention provides a vector comprising a polynucleotide as described herein. Such a vector can be a plasmid vector, a viral vector, a vector for baculovirus expression, a vector based on a transposon, or any other vector suitable for introducing the polynucleotides herein into a given organism or genetic background by any means. For example, the polynucleotides encoding the antibodies described herein can be inserted into an expression vector. The DNA fragment encoding the antibodies can be operably connected to the control sequence that guarantees the expression of immunoglobulin polypeptides in the expression vector. Such control sequences include a signal sequence, a promoter (such as naturally associated or heterologous promoters), an enhancer assembly and a transcription termination sequence, and are selected to be compatible with the host cell selected for expressing the antibody. Once the vector has been incorporated into a suitable host, the host is maintained under the conditions of high-level expression of the protein suitable for being encoded by the combined polynucleotides.

[0217] Suitable expression vectors can typically replicate in a host organism as an episome or as an integral part of the host chromosomal DNA. Typically, expression vectors contain a selection marker, such as ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance, or neomycin resistance, to allow detection of cells transformed with the desired DNA sequence. Suitable vectors, promoters, and enhancer components are known in the art; many are commercially available for use in generating subject recombinant constructs.

[0218] The term "host cell" refers to a cell into which a vector has been introduced. It should be understood that the term host cell is intended to refer not only to a specific target cell, but also to the progeny of such a cell. Because some modifications may occur in the offspring due to mutations or environmental influences, such offspring may be different from the parent cell, but are still included in the scope of the term "host cell" used herein. Such host cells can be eukaryotic cells, prokaryotic cells, plant cells or archaeal cells. Escherichia coli, Bacillus (e.g., Bacillus subtilis) and other Enterobacteriaceae (e.g., Salmonella, Serratia and various Pseudomonas) are examples of prokaryotic host cells. Other microorganisms (e.g., yeast) can also be used for expression. Saccharomyces (e.g., Saccharomyces cerevisiae) and Pichia are examples of suitable yeast host cells. Exemplary eukaryotic cells can be mammalian, insect, bird or other animal sources.

[0219] cell

[0220] In another aspect, provided herein is a cell capable of expressing an antibody as described herein. In another aspect, provided herein is a cell comprising a polynucleotide as described herein or a vector as described herein.

[0221] Cells described herein include, but are not limited to, eukaryotic cells, prokaryotic cells, plant cells, or archaeal cells. Escherichia coli, Bacillus (e.g., Bacillus subtilis), and other Enterobacteriaceae (e.g., Salmonella, Serratia, and various Pseudomonas) are examples of prokaryotic host cells. Other microorganisms (e.g., yeast) can also be used for expression. Saccharomyces (e.g., Saccharomyces cerevisiae) and Pichia are examples of suitable yeast host cells. Exemplary eukaryotic cells can be of mammalian, insect, avian, or other animal origin.

[0222] method

[0223] Also provided herein are methods for producing and using the antibodies described herein.

[0224] In another aspect, provided herein is a method of producing an antibody, comprising culturing the cell described herein and recovering the antibody from the cell.

[0225] Antibodies provided herein can be produced by any method known to those skilled in the art, including in vivo and in vitro methods. The desired antibody can be expressed in any organism suitable for producing the desired amount and form of the antibody. Expression hosts include prokaryotes and eukaryotes, such as Escherichia coli, yeast, plants, insect cells, mammalian cells (including human cell lines and transgenic animals). The post-translational modification types present in the expression host at its protein production level and expressed protein may be different. The selection of the expression host can be made based on these and other factors (such as regulation and safety considerations, production costs, and the needs and methods of purification).

[0226] Many expression vectors are available and are well known to those skilled in the art, and can be used for the expression of protein. The selection of expression vector will be affected by the selection of host expression system. Usually, expression vector can include transcription promoter and optional enhancer, translation signal, and transcription and translation termination signal. Expression vectors used for stable conversion typically have selectable markers, which allow selection and maintenance of transformed cells. In some cases, replication origin can be used to amplify the replication number of vector.

[0227] The expression vector can be introduced into the host cell via, for example, transformation, transfection, transduction, infection, electroporation and sonoporation. The skilled person can select methods and conditions suitable for introducing the expression vector into the host cell.

[0228] After introducing the vector including the selectable marker, before the cell is converted to the selective medium, the cell can be allowed to grow in the enriched medium for 1-2 days. The purpose of the selectable marker is to confer resistance to selection, and its presence allows the cell growth and recovery of the successfully expressed introduced sequence. The tissue culture technique suitable for the cell type can be used to propagate the resistance cell of the stably transformed cell. In some embodiments, the antibodies described herein are expressed in a mammalian expression system. Can be by viral infection (for example, by adenovirus constructs), or by direct DNA transfer (for example, liposomes, calcium phosphate, DEAE-dextran), and by physical means (for example, electroporation and microinjection) the expression construct is transferred to mammalian cells. In some embodiments, the antibodies described herein are delivered using viral transduction, for example, using a vector.

[0229] Expression vectors for mammalian cells typically include an mRNA cap site, a TATA box, a translation initiation sequence (Kozak consensus sequence), and a polyadenylation element. IRES elements may also be added to allow bicistronic expression with another gene (e.g., a selectable marker). Such vectors typically include transcription promoters-enhancers for high-level expression, such as SV40 promoter-enhancers, human cytomegalovirus (CMV) promoters, and long terminal repeats of Rous sarcoma virus (RSV). These promoters-enhancers are active in many cell types. Tissue and cell type promoter and enhancer regions may also be used for expression. Exemplary promoter / enhancer regions include, but are not limited to, promoter / enhancer regions from genes, such as elastase I, insulin, immunoglobulins, murine mammary cancer virus, albumin, alpha fetoprotein, alpha 1 antitrypsin, beta globulin, myelin basic protein, myosin light chain 2, and gonadotropin-releasing hormone gene control. Selectable markers may be used to select and maintain cells with expression constructs. Examples of selectable marker genes include, but are not limited to, hygromycin B phosphotransferase, adenosine deaminase, xanthine-guano purine phosphoribosyltransferase, aminoglycoside phosphotransferase, dihydrofolate reductase (DHFR) and thymidine kinase. For example, expression can be performed in the presence of methotrexate to select only cells expressing the DHFR gene.

[0230] Once the vector has been incorporated into a suitable host cell, the host cell is maintained under conditions suitable for expression of the antibody encoded by the incorporated polynucleotide. A skilled artisan is able to select conditions suitable for expression of the antibodies described herein.

[0231] In another aspect, the present invention provides a method for treating HSV-1 and / or HSV-2 infection in a subject, comprising administering to the subject an effective amount of an antibody as described herein or a composition as described herein. In some embodiments, the methods described herein are used to treat diseases caused by HSV-1 and / or HSV-2 infection, including but not limited to oral herpes and genital herpes.

[0232] Oral herpes infections are mostly asymptomatic, and most people with HSV-1 infection are unaware that they are infected. Symptoms of oral herpes include painful blisters in or around the mouth, or open sores called ulcers. Sores on the lips are often called "cold sores." Before the sores appear, infected people usually feel a tingling, itching, or burning sensation around their mouth. After the initial infection, the blisters or ulcers will recur periodically. The frequency of recurrences varies from person to person.

[0233] Genital herpes, caused by HSV-1 and / or HSV-2, can be asymptomatic or can have symptoms so mild that they are not recognized. When symptoms do occur, genital herpes is characterized by one or more genital or anal blisters or ulcers. After an initial (potentially severe) episode of genital herpes, symptoms may recur.

[0234] On the other hand, the present invention provides a method for detecting HSV-1 and / or HSV-2 in a sample, comprising contacting the sample with an antibody described herein or a composition described herein, and detecting the presence of the antibody. Methods for detecting antibodies include, but are not limited to, immunoprecipitation assays, in which Ag-Ab complex aggregates are usually detected by hemagglutination; immunocytochemistry, for in situ antibody detection in tissue sections; immunoblotting (dot blotting technique), in which Ag-Ab aggregates are captured on a membrane and then detected with a secondary Ab to produce spots; and immunosorbent assays, which are similar to immunoblotting, but the primary antibody can be quantified by using a labeled secondary antibody. There are a variety of immunosorbent kits available that allow rapid, specific, accurate and sensitive detection, especially for IgE antibodies. It should be understood that the technician can select suitable methods and conditions for antibody detection. More information on antibody detection can be found in Hermann K., Ollert M., Ring J. (2005) Antibody detection. In: Nijkamp FP, Parnham MJ (eds) Principles of Immunopharmacology, Basel, https: / /

[0235] / / doi.org / 10.1007 / 3-7643-7408-X_11.

[0236] Example

[0237] The present invention can be further described by the following non-limiting examples, in which standard techniques known to the skilled person and techniques similar to those described in these examples can be used as appropriate. It should be understood that the skilled person will envision additional embodiments consistent with the disclosure provided herein.

[0238] Example 1 Production and inactivation of HSV-1

[0239] HSV-1 virus was produced at Virogin Biotech using Vero cells and purified and concentrated using high-speed centrifugation as described by Bernstock et al.

[0240] 1 ml of purified virus was placed in a 10 cm uncovered petri dish and exposed to 27 mJ / cm 2 The virus was inactivated by UVc. Inactivation was verified by plaque assay using Vero cells.

[0241] Example 2 Expression and purification of HSV-1 gD protein

[0242] The HSV-1 gD protein coding sequence was cloned into the pCDNA3.1 vector and expressed using the FreeStyle293 cell expression system (Thermofisher). In brief, FreeStyle 293 cells were grown in FreeStyle 293 expression medium (Thermofisher) until the cells reached a density of 1 million cells / ml. Cells were transfected with expression plasmids (pCDNA3.1-gD-Fc) using a polyethyleneimine-based method (PEI) as described by Baldi et al. 3 days after transfection, the culture medium was harvested and the recombinant protein was purified on a protein G column as described by Agrawal et al. In brief, the culture medium was filtered using a 0.45 μm filter and loaded into a protein A column. The column was washed with 5 CV of PBS and then washed with a citrate buffer at pH 3.2.

[0243] Example 3 Immunization in llamas

[0244] A llama (Lamaglama) was immunized with inactivated HSV-1 at Cedarlane Laboratories (Burnington, Canada). Immunization consisted of a pre-injection of 100 μg HSV-1 (100 μL of 1 mg / mL stock solution) mixed with complete Freund's adjuvant on day 0, followed by three boosts on days 21, 28, and 35, each with 100 μg HSV-1 mixed with incomplete Freund's adjuvant. Prior to the first injection on day 0, pre-immune blood was drawn and the resulting serum was frozen. Immune blood was drawn on day 42 and the resulting serum was frozen. PBMCs were also isolated from the blood drawn on day 42 and immediately frozen.

[0245] Example 4 Detection of HSV-1 gD protein and HSV-1 antibodies

[0246] ELISA was used to determine whether a polyclonal response to HSV-1 and glycoprotein D was generated using pre-immune sera drawn before the initial injection on day 0 and immune sera drawn on day 42 after immunization. Polyclonal llama antibodies specific for the target were detected using the following: (i) anti-llama-Fc-IgG HRP conjugate for detection of conventional and heavy chain IgG, and (ii) anti-heavy chain IgG specific mouse mAb (referred to as "1C10") for detection of heavy chain IgG (Henry et al., 2019). ELISA plate wells were coated with 0.1 μg HSV-1 or glycoprotein D diluted in PBS per well at 4°C overnight (100 μL / well). The next day, the wells were blocked with 4% w / v non-fat skim milk diluted in PBS (300 μL / well) for 1 hour at 37°C. After removing the blocking buffer, sera from day 0 and day 42 were added to the wells (100 μL / well) in 10-fold serial dilutions (starting from 1:10 to 1:10000000) diluted in PBS for 1 hour at room temperature. The wells were washed 3 times with PBS-T (PBS, 0.05% v / v Tween 20), 300 μL / well each wash. Next, for total llama polyclonal detection, anti-llama-Fc IgG HRP conjugate (Bethyl Laboratories, Montgomery County, Texas) diluted 1:20000 in PBS was added to each well (100 μL / well) for 1 hour at room temperature. Alternatively, for heavy chain IgG detection, wells were incubated with mouse 1C10 mAb (NRC, Ottawa, Canada) diluted 1:1000 in PBS (100 μL / well) for 1 hour at room temperature. All wells were washed again as above. All llama polyclonal wells were developed by adding TMB peroxidase substrate (Mandel Scientific, Guelph, Canada) for 5 min at room temperature (100 μL / well), the reaction was stopped with 1 M sulfuric acid (100 μL / well) and the absorbance was read at 450 nm. After washing as above, donkey anti-mouse IgG HRP conjugate (100 μL / well) diluted 1:3000 in PBS was added to the heavy chain polyclonal wells for 1 hour at room temperature. The wells were washed again and developed with TMB substrate, stopped and the absorbance was read as above. Total polyclonal responses to HSV-1 and glycoprotein D, as well as heavy chain IgG polyclonal responses ( Figure 1 ). The HSV-1 signal was high for both pre-immune and immune sera using anti-llama-Fc IgG HRP antibody, but the pre-immune signal was negligible when detected using 1C10 mAb.

[0247] Example 5 Construction of phage display library

[0248] Using PBMCs isolated from blood drawn on day 42, phage display libraries were constructed in pMED1 phagemid vectors exactly as described by Baral et al. and Hussack et al. Briefly, RNA was extracted from PBMCs, cDNA was synthesized, and two rounds of PCR were performed to amplify VHH encoding genes. Next, the SfiI-digested PCR product was ligated into the SfiI-digested pMED1 vector and electroporated into electrocompetent TG1 E. coli cells to produce library cells. Phages were rescued using M13KO7 helper phage (New England Biolabs, Ipswich, MA), purified, titered, and used as input for the first round of panning. Colony PCR was performed on random colonies to confirm VHH insertions as described by Baral et al. Sanger DNA sequencing was performed on PCR amplicons to assess library diversity. Approximately 2×10 7 The library size of unique transformants.

[0249] Example 6 Panning

[0250] Using purified library phage and glycoprotein D coated on microtiter plate wells, three rounds of phage panning were performed to essentially separate target specific VHHs, as described by Baral et al. and Hussack et al. Prior to round 1, wells were coated overnight at 4°C with 5 μg glycoprotein D (100 μL / well) diluted with PBS or PBS. The next morning, single colonies from M9 minimal medium plates were used, and TG1 E. coli cultures were grown in 3mL 2YT+2% v / v glucose (300 μL 20% sterile filtered glucose) without antibiotics in 15mL Falcon tubes at 37°C, 250rpm until OD600=0.5 (approximately 3 hours). The contents in the wells coated overnight were then removed, 2% w / v non-fat skim milk (NFSM) (300 μL / well) diluted with PBS was added as a blocking agent, and cultured for 2 hours at 37°C. After removing the blocking agent, 50 μL of library phage (3×10 11cfu) were added to two wells containing 50 μL of 4% w / v NFSM diluted in PBS and incubated for 30 minutes at room temperature. After 30 minutes, the phages were removed and discarded. Both wells were washed with 5×300 μL / well PBST (PBS+0.05% v / v Tween 20) and then 5×300 μL / well PBS. After the last wash, the bound phages were extracted with high pH and low pH. First, 100 μL of freshly prepared triethylamine (TEA) was added to the wells, incubated for 10 minutes, removed, transferred to a 1.5 mL microcentrifuge tube, and then neutralized with 50 μL 1M Tris-HCl, pH 7.4. Secondly, 100 μL of 100mM glycine (pH 2) was added to the wells, incubated for 10 minutes, removed, transferred to a new 1.5 mL microcentrifuge tube, and then neutralized with 10 μL 2M Tris base. Combine the two washes to give a final volume of 260 μL. Using the previously started TG1 E. coli cells, half of the phage wash (130 μL) was added to 3 mL of culture and cultured at 37°C without shaking for 30 minutes. Then, an aliquot of infected TG1 E. coli cells was serially diluted on 2YT+ ampicillin plates and grown overnight at 32°C. These plates were used to determine the phage titer of the washes and were the source of colonies for colony PCR, sequencing, and phage ELISA (in the subsequent panning rounds). For the remaining 3 mL of culture, shake and culture at 37°C for 30 minutes at 250 rpm. After shaking for 30 minutes, 3 μL of ampicillin stock solution (100 mg / mL) and M13KO7 helper phage (20× excess phage, about 5×1010 pfu) were added and cultured without shaking for 15 minutes at 37°C, then the cells were centrifuged (4000 rpm, 10 minutes) and the supernatant was discarded. The cell pellet was then resuspended in 10 mL 2YT+ampicillin+0.1% v / v glucose in a 50 mL Falcon tube and grown at 250 rpm for 30 minutes at 37°C. Next, 10 μL of kanamycin stock solution (50 mg / mL) was added, and the culture was grown overnight at 32°C and 250 rpm shaking. The next day, the amplified phage particles were purified using a standard PEG precipitation method (25% w / v PEG, 2.5 M NaCl). The purified phage was finally resuspended in 200 μL PBS and titrated with TG1 E. coli. The amplified phage was used as input for the second round of panning. The second and third rounds of panning were performed in full accordance with the above steps, except that SuperBlock (Thermo Fisher, Ottawa, Canada) was used to replace NFSM as a blocking agent in the second round.Colonies from phage titer plates from round 3 (2YT+ampicillin plates; not amplified phage) were used for phage ELISA, colony PCR, and Sanger DNA sequencing.

[0251] Example 7 Phage ELISA

[0252] Before performing phage ELISA, prepare glycerol stock. Using 93 colonies from the phage titer plate from round 3, pick each colony and add it to 2YT+ampicillin (100 μL / well) in a 96-well sterile plate, shake (200 rpm) for 3-4 hours at 37°C, and move 5 μL aliquots of the culture to a new plate, which is a duplicate plate containing 2YT+ampicillin (200 μL / well). Glycerol (final 25%) is added to the original plate and frozen at -80°C to produce a glycerol stock in the form of a 96-well plate. The second plate (containing about 200 μL / well culture) is grown at 37°C, shaken at 200 rpm for about 3-4 hours, until OD600=0.5 and M13KO7 helper phage is added to each well (20× excess phage). The plates were incubated at 37°C without shaking for 15 minutes and then shaken at 230 rpm for 30 minutes. Next, 2 μL of kanamycin stock solution was added to each well and the plates were grown overnight at 37°C with shaking at 230 rpm. The next day, the plates were centrifuged to pellet the cultures, and the supernatant (containing phage) was removed and used directly for phage ELISA.

[0253] For phage ELISA, 96-well plates were coated overnight with 0.5 μg of glycoprotein D (100 μL / well) diluted in PBS at 4°C. The next day, the wells were blocked with 5% NFSM diluted in PBST for 1 hour at 37°C. After removing the blocking agent, 150 μL of the previously prepared phage supernatant was added to the wells. PBS alone and pure helper phage were used as assay controls. Phages were cultured at 37°C for 1 hour and then washed 4 times with PBST (300 μL / well). The binding of phage to the surface-coated glycoprotein D was detected with anti-M13-IgG HRP conjugate (Cytiva, Vancouver, Canada) diluted 1:5000 with PBS and cultured for 1 hour at room temperature. The last set of 4 washes was performed before adding TMB matrix (Mandel Scientific) for 5 minutes (100 μL / well), and then the reaction was stopped with 1M sulfuric acid (100 μL / well) before reading the absorbance at 450nm. Figure 2 The 96-well plate layout, VHH clone names and resulting A450 values ​​are shown.

[0254] Example 8 DNA sequencing

[0255] A single TG1 E. coli colony for phage ELISA was PCR amplified and subjected to Sanger DNA sequencing. Colony PCR was performed using the primers described in Baral et al. and a standard PCR reaction mixture in a volume of 10 μL. Before running the PCR program, the colony was touched with a small pipette tip and added to the PCR reaction mixture. The PCR program consisted of: 95°C for 5 minutes, 35 cycles of 95°C (20 seconds), 55°C (20 seconds) and 72°C (20 seconds), and finally 72°C for 5 minutes. PCR products were analyzed by DNA agarose gel electrophoresis and then sequenced using the M13RP sequencing primer described in Baral et al. The sequences were analyzed and grouped based on CDR3. The names are in Figure 2 The antibodies highlighted in A have the amino acid sequences listed in Table 3.

[0256] Example 9 Expression and purification of soluble VHH

[0257] The unique VHH gene scored as a positive clone in phage ELISA was subcloned into an expression vector (pET22b vector). After sequence confirmation, recombinant sdAb was expressed and purified by IMAC. In brief, the clone was inoculated in 25ml LB (100 μg of ampicillin per ml), and cultured overnight at 37°C while shaking at 200rpm. Then 20 ml of culture was added to 1L M9 culture medium containing 0.2% glucose, 0.6% Na2HPO4, 0.3% KH2PO4, 0.1% NH4Cl, 0.05% NaCl, 1mM MgCl2 and 0.1mM CaCl2. The culture medium has also been supplemented with 0.4% casamino acids, 5 μg / ml vitamin B1 and 100 μg / ml ampicillin. The suspension was then cultured for 24 hours. 100 ml of 10×TB nutrient containing 12% tryptic protein, 24% yeast extract and 4% glycerol was added to the culture along with 2 ml of 100 μg / ml ampicillin and 1 ml of 1M isopropyl-beta-D-thiogalactopyranoside (IPTG). The cells were cultured for an additional 65-70 hours at 28°C while shaking at 200 rpm. The suspension was then centrifuged and the cell pellet was subsequently lysed using lysozyme. The cell lysate was centrifuged and the resulting supernatant was loaded onto a 5 ml HiTrap TMThe His-tagged protein was eluted with a linear gradient of 2.5 to 500 mM imidazole. The eluted protein was then dialyzed in PBS buffer.

[0258] Example 10 Size Exclusion Chromatography (SEC) and Surface Plasmon Resonance (SPR) Analysis

[0259] At room temperature, 300-500 μg of VHH in 500 μL was injected onto a Superdex S7510 / 300GL column (Cytiva) at a flow rate of 0.8 mL / min to further SEC purify the purified glycoprotein D-specific VHH to remove trace aggregates before SPR. HBS-EP+ (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% P20 surfactant, pH 7.4; Cytiva) was used as the electrophoresis buffer. SEC fractions (0.5 mL) were collected and the monomer peak fraction was measured by NanoDrop to determine the concentration before SPR. The specific instruments, materials and methods used for SEC are listed below:

[0260] instrument: FPLC (GE Healthcare)

[0261] Column: Superdex S75 10 / 300GL, Code: 17-5174-01, Lot: 10221448, ID 0110 (GE Healthcare)

[0262] Column: Superdex S200 INCREASE 10 / 300GL, Code: 28-9909-44, Lot: 10243519, ID0150 (GE Healthcare)

[0263] Running buffer: HBS-EP+ (see above)

[0264] Pump rate: 0.8mL / min, Sample volume: variable, Fraction volume: 500uL

[0265] Separation of monomeric peaks of all five VHHs ( Figure 3A, G19 = 3-G-19_M13R, G41 = 3-G-41_M13R, G44 = 3-G-44_M13R, G77 = 3-G-77_M13R, G75 = 3-G-75_M13R). The purity of G-Fc was checked on the S200 INCREASE column ( Figure 3 B) Some information of G-Fc protein, VHH and goat anti-human IgG is in Table 4.

[0266] Table 4

[0267]

[0268]

[0269] Various VHHs were analyzed by SPR against target G-Fc under the following conditions:

[0270] Instrument: BIACORE T200

[0271] Electrophoresis buffer: HBS-EP+

[0272] Flow path: Fc 1–4, Detection: Fc 2-1, 3-1 and 4-1

[0273] Capture of targets B-Fc and G-Fc on Fc 2, 3 & 4: Flow rate: 10AL / min, Injection time: variable (90–135s),

[0274] Concentration: 5Ag / mL B-Fc and 1Ag / mL G-Fc

[0275] Injection of SEC-purified sdAb on Fc 1-4: Flow rate: 40 AL / min

[0276] Injection volume: 120uL (180s), dissociation: B-Fc 600s, G-Fc 900s

[0277] Biacore Kinetic Methods: Single Cycle Kinetics (SCK)

[0278] Regeneration: Flow rate: 30uL / min, 60uL (120s) 10mM glycine, pH 1.5

[0279] More specifically, SPR experiments were performed on a Biacore T200 (Cytiva) at 25°C in HBS-EP+ electrophoresis buffer. To determine VHH affinity and kinetics, G-Fc was captured on an anti-human Fc IgG surface and VHHs were perfused. Approximately 5000 RU of goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA) was amine-coupled to an S-series sensor chip CM5 (Cytiva) using 10 mM acetate buffer, pH 4.5, following the manufacturer's instructions. G-Fc protein was then captured on the goat anti-human IgG surface by injecting G-Fc (1 μg / mL) at a flow rate of 10 μL / min for 135 s, resulting in G-Fc capture levels ranging from 229–337 RU. A perfusion chamber without captured G-Fc antigen was used as a reference surface. A perfusion chamber with a control Fc fusion protein was used as a negative control surface ( Figure 4 ).

[0280] Depending on the VHH, VHHs were injected at various concentrations ranging from 2–0.125 nM to 128–8 nM using single cycle kinetics at a flow rate of 40 μL / min, a contact time of 180 s, and a dissociation time of 900 s. The injection concentrations of each VHH are listed in Table 5.

[0281]

[0282]

[0283] The surface was regenerated by injecting 10 mM glycine, pH 1.5, at a flow rate of 30 μL / min for 120 s. The sensorgrams minus the reference perfusion chamber were fitted to a 1:1 binding model to determine kinetics and affinity using BIAevaluation Software v3.0 (Cytiva). Five VHHs bound to glycoprotein D, with most exhibiting a K D High affinity binding ranging from 50 pM to 4 nM (Table 6 and Figure 5 ). One VHH (G41) bound but could not fit a 1:1 interaction model. Some SRP sensorgram results are shown in Figure 6 .

[0284] Table 6 Kinetic analysis data

[0285]

[0286] As shown in Table 6, G41, G44 and G77 showed extremely strong binding to G-Fc with affinities (K D ) ranged from 0.05–0.2 nM. G75 showed strong binding to G-Fc, with a K DApproximately 4 nM. G19 showed specific binding to G-Fc; however, it could not fit a 1:1 binding model. When this sample was thawed prior to SEC purification, a large amount of precipitate was observed.

[0287] SPR was also used for epitope identification to determine how many overlapping or non-overlapping epitopes were targeted by the five glycoprotein D VHHs under the following conditions:

[0288] Capture targets B-Fc and G-Fc on Fc 2, 3 and 4: Flow rate: 10

[0289] AL / min, injection time: variable (90–135 seconds),

[0290] Concentration: 5Ag / mL B-Fc and 1ug / mL G-Fc

[0291] Double injection (co-injection) of SEC-purified sdAb on Fc 1-4: Flow rate: 30

[0292] AL / min, injection volume: 120uL

[0293] Concentration: All sdAbs were injected at 25× KD

[0294] Injection 1: sdAb A, followed by injection 2: sdAb A + sdAb B

[0295] Regeneration: Flow rate: 30uL / min, 60uL (120s) 10mM glycine, pH 1.5

[0296] Using the captured G-Fc antigen as described above, pairs of VHHs were injected sequentially at surface saturation concentrations. D Injection 1, which consisted of 100 μL of VHH1 and 100 μL of VHH2 (25×KD concentration), lasted for 180 seconds, followed by injection 2, which was a mixture of VHH1+VHH2 (both at 25×KD concentration) for 180 seconds, all at a flow rate of 30 μL / min. The reverse direction (VHH2, then VHH2+VHH1) was repeated. The surface was regenerated using the above conditions. Based on the response (or lack of response) of the second injection, all VHH pairs were mapped to overlapping or non-overlapping epitope bins, which are graphically shown in Figure 7 Two different epitopes were found on G-Fc: G19, G41, G44, and G77 bind to different epitopes than G75. The results of SPR epitope identification are shown in Figure 8 shown.

[0297] Example 11 In vitro neutralization test

[0298] By exposing the HSV-1 virus to different antibodies and then testing the infectivity of HSV-1, the HSV-1 neutralization ability was detected by VHH specific for purified glycoprotein D. Briefly, the VG17 virus (HSV-1 wild-type unpurified virus with a titer of ~2.0x10E+8) was diluted 100,000 times (10ul was diluted in 1ml of original DMEM, and then 10ul was diluted in 10ml of original DMEM). 3μg of each antibody was mixed with 50ul of diluted virus, and the volume was adjusted to 1ml using the original DMEM medium. The mixture was incubated at room temperature for 1 hour, after which 250ul of each dilution was used to infect VERO cells in a 12-well plate.

[0299] The virus was allowed to infect the cells for 1 hour, after which the culture medium was removed and washed with 1 ml of acidified PBS and then with 1 ml of PBS. The cells were covered by adding 1 ml of methylcellulose in DMEM per well. Among all the antibodies tested, only the G75 antibody had the ability to neutralize or reduce the infectivity of the HSV-1 virus.

[0300] Further exemplary embodiments are described below.

[0301] Embodiment 1. An antibody comprising a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs) CDR1, CDR2 and CDR3, wherein the CDR1 is selected from SEQ ID NOs: 17-25, the CDR2 is selected from SEQ ID NOs: 30-36, the CDR3 is selected from SEQ ID NOs: 45-63, and wherein the antibody binds to glycoprotein D (gD protein).

[0302] Embodiment 2. The antibody of embodiment 1, wherein the CDR1, CDR2 and CDR3 comprise:

[0303] (a) SEQ ID NO: 17, SEQ ID NO: 30 and SEQ ID NO: 45, respectively;

[0304] (b) SEQ ID NO: 17, SEQ ID NO: 31 and SEQ ID NO: 46, respectively;

[0305] (c) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 47, respectively;

[0306] (d) SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0307] (e) SEQ ID NO: 20, SEQ ID NO: 33 and SEQ ID NO: 45, respectively;

[0308] (f) SEQ ID NO: 21, SEQ ID NO: 31 and SEQ ID NO: 49, respectively;

[0309] (g) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 50, respectively;

[0310] (h) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 51, respectively;

[0311] (i) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 48, respectively;

[0312] (j) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 52, respectively;

[0313] (k) SEQ ID NO: 23, SEQ ID NO: 31 and SEQ ID NO: 53, respectively;

[0314] (l) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 54, respectively;

[0315] (m) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 55, respectively;

[0316] (n) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 56, respectively;

[0317] (o) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 57, respectively;

[0318] (p) are SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 58, respectively;

[0319] (q) are SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 59, respectively;

[0320] (r) SEQ ID NO: 17, SEQ ID NO: 34 and SEQ ID NO: 60, respectively;

[0321] (s) are SEQ ID NO: 24, SEQ ID NO: 35 and SEQ ID NO: 61, respectively;

[0322] (t) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 62, respectively; or

[0323] (u) are SEQ ID NO: 25, SEQ ID NO: 36 and SEQ ID NO: 63, respectively.

[0324] Embodiment 3. The antibody of any one of embodiments 1-2, wherein the antibody comprises a framework region 1 (FR1) selected from SEQ ID NO: 1-16, a framework region 2 (FR2) selected from SEQ ID NO: 26-29, a framework region 3 (FR3) selected from SEQ ID NO: 37-44, and a framework region 4 (FR4) selected from SEQ ID NO: 64-66.

[0325] Embodiment 4. The antibody of any one of embodiments 1-3, wherein FR1, FR2, FR3 and FR4 comprise:

[0326] (a) SEQ ID NO: 1, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0327] (b) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0328] (c) SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0329] (d) SEQ ID NO: 4, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0330] (e) SEQ ID NO: 5, SEQ ID NO: 27, SEQ ID NO: 37 and SEQ ID NO: 64, respectively;

[0331] (f) SEQ ID NO: 6, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0332] (g) SEQ ID NO: 7, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0333] (h) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0334] i) SEQ ID NO: 9, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively;

[0335] (j) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 64, respectively;

[0336] (k) SEQ ID NO: 10, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0337] (l) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0338] (m) are SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0339] (n) are SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0340] (o) SEQ ID NO: 13, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively;

[0341] (p) are SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 42 and SEQ ID NO: 64, respectively;

[0342] (q) are SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively;

[0343] (r) SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively;

[0344] (s) are SEQ ID NO: 14, SEQ ID NO: 28, SEQ ID NO: 43 and SEQ ID NO: 66, respectively;

[0345] (t) SEQ ID NO: 15, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; or

[0346] (u) are SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 44 and SEQ ID NO: 64, respectively.

[0347] Embodiment 5. The antibody of any one of embodiments 1-4, wherein the antibody comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 67-87.

[0348] Embodiment 6. The antibody described in any one of embodiments 1-5 comprises a heavy chain variable region, wherein the heavy chain variable region comprises the amino acid sequence shown in any one of SEQ ID NOs: 67-87.

[0349] Embodiment 7. The antibody of any one of embodiments 1 to 6, wherein the gD protein is derived from a virus.

[0350] Embodiment 8. The antibody of embodiment 7, wherein the virus is herpes simplex virus (HSV).

[0351] Embodiment 9. The antibody of embodiment 8, wherein the HSV is HSV-1 or HSV-2.

[0352] Embodiment 10. The antibody of any one of embodiments 1-9, wherein the gD protein is a recombinant gD protein.

[0353] Embodiment 11. The antibody of any one of embodiments 1-10, wherein the antibody binds to HSV-1 and / or HSV-2.

[0354] Embodiment 12. The antibody of any one of embodiments 1-11, wherein the antibody has a K in the range of about 1 pM to about 1 μM. D Binds to the gD protein.

[0355] Embodiment 13. The antibody of any one of embodiments 1-12, wherein the K D The range is about 50 pM to about 4 nM.

[0356] Embodiment 14. The antibody of any one of embodiments 1-13, wherein the K D The range is 0.05nM to 0.2nM.

[0357] Embodiment 15. The antibody of any one of embodiments 1-14, wherein the antibody has a K of about 4 nM or less. D Binds to the gD protein.

[0358] Embodiment 16. The antibody of any one of embodiments 1-15, wherein the antibody is a single heavy domain antibody (sdAb) or a multispecific antibody.

[0359] Embodiment 17. The antibody of any one of embodiments 1-16, wherein the antibody is a neutralizing antibody.

[0360] Embodiment 18. The antibody of any one of embodiments 1-17, wherein the antibody is capable of neutralizing HSV-1 and / or HSV-2.

[0361] Embodiment 19. The antibody of any one of embodiments 17-18, wherein the antibody comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:85.

[0362] Embodiment 20. The antibody of any one of embodiments 1-16, wherein the antibody is a non-neutralizing antibody.

[0363] Embodiment 21. The antibody of any one of embodiments 1-16, wherein the antibody is a multispecific antibody comprising the amino acid sequence shown in SEQ ID NO: 85 and one or more amino acid sequences selected from SEQ ID NOs: 67-84 and 86-87.

[0364] Embodiment 22. A composition comprising the antibody of any one of embodiments 1-21.

[0365] Embodiment 23. A pharmaceutical composition comprising the antibody of any one of embodiments 1-21 and a pharmaceutically acceptable carrier.

[0366] Embodiment 24. A polynucleotide encoding the antibody of any one of embodiments 1-21.

[0367] Embodiment 25. A vector comprising the polynucleotide of embodiment 24.

[0368] Embodiment 26. A cell capable of expressing the antibody of any one of embodiments 1-21.

[0369] Embodiment 27. A cell comprising the polynucleotide of embodiment 24 or the vector of embodiment 25.

[0370] Embodiment 28. A method of producing an antibody, comprising culturing the cell of embodiment 26 or embodiment 27, and recovering the antibody from the cell.

[0371] Embodiment 29. A method for treating infection with HSV-1 and / or HSV-2 in a subject, comprising administering to the subject an effective amount of the antibody of any one of embodiments 1-21 or the composition of embodiment 22 or embodiment 23.

[0372] Embodiment 30. A method for detecting HSV-1 and / or HSV-2 in a sample, comprising contacting the sample with the antibody of any one of embodiments 1-21 or the composition of embodiment 22 or embodiment 23, and detecting the presence of the antibody.

[0373] While it has been particularly shown and described herein with reference to particular embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the disclosure herein.

[0374] [References]

[0375] 1. Henry KA, van Faassen H, Harcus D, et al. Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes arephenotypically indistinguishable but immunogenetically distinct. Immunogenetics.2019;71(4):307-320.doi:10.1007 / s00251-018-01102-9

[0376] 2.Baral et al Curr Protoc Immunol Single-domain antibodies and their utility-PubMed(nih.gov)

[0377] 3.Hussack G,Arbabi-Ghahroudi M,van Faassen H,et al.Neutralization ofClostridium difficile toxin A with single-domain antibodies targeting thecell receptor binding domain.J Biol Chem.2011;286(11):8961-8976.doi:10.1074 / jbc.M110.198754

[0378] 4.Safety and Efficacy of Oncolytic HSV-1 G207 Inoculated into theCerebellum of Mice(nih.gov).Cancer Gene Ther.Author manuscript;available inPMC 2020Oct 1.Published in finaledited form as:Cancer Gene Ther.2020 Apr;27(3-4):246–255.Published online 2019Mar 28.doi:10.1038 / s41417-019-0091-0.https: / / pubmed.ncbi.nlm.nih.gov / 15903252 /

[0379] 5.Agrawal V,Slivac I,Perret S,et al.Stable expression of chimericheavy chain antibodies in CHO cells.Methods Mol Biol.2012;911:287-303.doi:10.1007 / 978-1-61779-968-6_18

[0380] 6.Batzer,M.A.,Arcot,S.S.,Phinney,J.W.,Alegria-Hartman,M.,Kass,D.H.,&Milligan,S.M.,et al.(1996).Genetic variation of recent alu insertions inhuman populations.Journal of Molecular Evolution,42(1),22-29.

[0381] 7.Ohtsuka,E.,Matsuki,S.,Ikehara,M.,Takahashi,Y.,&Matsubara,K.(1985).An alternative approach to deoxyoligonucleotides as hybridation probes byinsertion of deoxyinosine at ambiguous codon positions.Journal of BiologicalChemistry,260(5),2605-2608.

[0382] 8.Cassol,S.A.,Lapointe,N.,Salas,T.,Hankins,C.,&Charest,J.(1992).Diagnosis of vertical hiv-1 transmission using the polymerase chain reactionand dried blood spot specimens.J Acquir Immune Defic Syndr,5(2),113-119.

[0383] 9.Rossolini,G.M.,Cresti,S.,Ingianni,A.,Cattani,P.,&Satta,G.(1994).Useof deoxyinosine-containing primers vs degenerate primers for polymerase chainreaction based on ambiguous sequence information.Molecular&Cellular Probes,8(2),91.

[0384] 10.“Sequences of Proteins of Immunological Interest,”5th Ed.PublicHealth Service,National Institutes of Health,Bethesda,MD(“Kabat”numberingscheme),

[0385] 11.Al-Lazikani et al.,(1997)JMB 273,927-948(“Chothia”numberingscheme);

[0386] 12.MacCallum et al.,J.Mol.Biol.262:732-745(1996),“Antibody-antigeninteractions:Contact analysis and binding site topography,”J.Mol.Biol.262,732-745.”(“Contact”numbering scheme);

[0387] 13.Lefranc MP et al.,“IMGT unique numbering for immunoglobulin and Tcell receptor variable domains and Ig superfamily V-like domains,”Dev CompImmunol,2003 Jan;27(1):55-77(“IMGT”numbering scheme);

[0388] 14.Honegger A and Plückthun A,“Yet another numbering scheme forimmunoglobulin variable domains:an automatic modeling and analysis tool,”JMol Biol,2001 Jun 8;309(3):657-70,(“Aho”numbering scheme);

[0389] 15.Martin et al.,“Modeling antibody hypervariable loops:a combinedalgorithm,”PNAS,1989,86(23):9268-9272,(“AbM”numbering scheme).

[0390] 16.Pope M.E.,Soste M.V.,Eyford B.A.,Anderson N.L.,Pearson T.W.,(2009)J.Immunol.Methods.341(1-2):86-96

[0391] 17.Polpitiya Arachchige,S.,Henke,W.,Kalamvoki,M.et al.Analysis ofherpes simplex type 1 gB,gD,and gH / gL on production of infectious HIV-1:HSV-1gD restricts HIV-1 by exclusion of HIV-1 Env from maturing viralparticles.Retrovirology 16,9(2019).

[0392] 18.Karasneh G.A.,Shukla D.(2011).Herpes simplex virus infects mostcell types in vitro:Clues to its success.Virol.J.8:481.doi:10.1186 / 1743-422X-8-481

[0393] 19.Carson J,Haddad D,Bressman M,Fong Y.ONCOLYTIC HERPES SIMPLEX VIRUS1(HSV-1)VECTORS:INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGICVIRUS DESIGN.Drugs Future.2010;35(3):183-195.doi:10.1358 / dof.2010.35.3.1470166

[0394] 20.Surface Plasmon Resonance,Nico J.MolMarcel J.E.Fischer,DOI:10.1007 / 978-1-60761-670-2 ISBN:978-1-60761-669-6.

[0395] 21.Kaslow,R.A.;Stanberry,L.R.;Le Duc,J.W.,eds.(2014).Viral Infectionsof Humans:Epidemiology and Control(5th ed.).Springer.p.56.ISBN 9781489974488

[0396] 22.Construction of a Fully Retargeted Herpes Simplex Virus 1Recombinant Capable of Entering Cells Solely via Human Epidermal GrowthFactor Receptor 2,Laura Menotti et al.,Jounal of Virology,12.22.2020,DOI:https: / / doi.org / 10.1128 / JVI.01133-08.

[0397] 23.Hermann K.,Ollert M.,Ring J.(2005)Antibody detection.In:NijkampF.P.,Parnham M.J.(eds)Principles of Immunopharmacology. Basel.https: / / doi.org / 10.1007 / 3-7643-7408-X_11

[0398] 24.Baldi L,Muller N,Picasso S,et al.Transient gene expression insuspension HEK-293 cells:application to large-scale proteinproduction.Biotechnol Prog.2005;21(1):148-153.doi:10.1021 / bp049830x

[0399] 25.Attenuated multi-mutated herpes simplex virus-1 for the treatmentof malignant gliomas.Mineta T,Rabkin SD,Yazaki T,Hunter WD,Martuza RL NatMed.1995 Sep;1(9):938-43.

[0400] 26.Serial passage through human glioma xenografts selects for aDeltagamma 134.5 herpes simplex virus type 1 mutant that exhibits decreasedneurotoxicity and prolongs survival of mice with experimental braintumors.Shah AC,Price KH,Parker JN,Samuel SL,Meleth S,Cassady KA,Gillespie GY,Whitley RJ,Markert JM,J Virol.2006 Aug;80(15):7308-15.

[0401] 27.Treatment of intracranial gliomas in immunocompetent mice usingherpes simplex viruses that express murine interleukins.Andreansky S,He B,vanCott J,McGhee J,Markert JM,Gillespie GY,Roizman B,Whitley RJ,GeneTher.1998Jan;5(1)121-30.

Claims

1. An antibody comprising a heavy chain variable region, wherein the heavy chain variable region comprises three complementarity determining regions (CDRs) CDR1, CDR2 and CDR3, wherein the CDR1 is selected from SEQ ID NOs: 17-25, the CDR2 is selected from SEQ ID NOs: 30-36, the CDR3 is selected from SEQ ID NOs: 45-63, and wherein the antibody binds to glycoprotein D (gD protein).

2. The antibody of claim 1, wherein the CDR1, CDR2 and CDR3 comprise: (a) SEQ ID NO: 17, SEQ ID NO: 30 and SEQ ID NO: 45, respectively; (b) SEQ ID NO: 17, SEQ ID NO: 31 and SEQ ID NO: 46, respectively; (c) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 47, respectively; (d) SEQ ID NO: 19, SEQ ID NO: 31 and SEQ ID NO: 48, respectively; (e) SEQ ID NO: 20, SEQ ID NO: 33 and SEQ ID NO: 45, respectively; (f) SEQ ID NO: 21, SEQ ID NO: 31 and SEQ ID NO: 49, respectively; (g) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 50, respectively; (h) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 51, respectively; (i) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 48, respectively; (j) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 52, respectively; (k) SEQ ID NO: 23, SEQ ID NO: 31 and SEQ ID NO: 53, respectively; (l) SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 54, respectively; (m) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 55, respectively; (n) are SEQ ID NO: 17, SEQ ID NO: 32 and SEQ ID NO: 56, respectively; (o) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 57, respectively; (p) are SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 58, respectively; (q) are SEQ ID NO: 18, SEQ ID NO: 32 and SEQ ID NO: 59, respectively; (r) SEQ ID NO: 17, SEQ ID NO: 34 and SEQ ID NO: 60, respectively; (s) are SEQ ID NO: 24, SEQ ID NO: 35 and SEQ ID NO: 61, respectively; (t) SEQ ID NO: 22, SEQ ID NO: 31 and SEQ ID NO: 62, respectively; or (u) are SEQ ID NO: 25, SEQ ID NO: 36 and SEQ ID NO: 63, respectively.

3. The antibody of any one of claims 1-2, wherein the antibody comprises a framework region 1 (FR1) selected from SEQ ID NOs: 1-16, a framework region 2 (FR2) selected from SEQ ID NOs: 26-29, a framework region 3 (FR3) selected from SEQ ID NOs: 37-44, and a framework region 4 (FR4) selected from SEQ ID NOs: 64-66.

4. The antibody of any one of claims 1-3, wherein the FR1, the FR2, the FR3 and the FR4 comprise: (a) SEQ ID NO: 1, SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 64, respectively; (b) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively; (c) SEQ ID NO: 3, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively; (d) SEQ ID NO: 4, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively; (e) SEQ ID NO: 5, SEQ ID NO: 27, SEQ ID NO: 37 and SEQ ID NO: 64, respectively; (f) SEQ ID NO: 6, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; (g) SEQ ID NO: 7, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively; (h) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively; (i) SEQ ID NO: 9, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 65, respectively; (j) SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 40 and SEQ ID NO: 64, respectively; (k) SEQ ID NO: 10, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; (l) SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively; (m) are SEQ ID NO: 11, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively; (n) are SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively; (o) SEQ ID NO: 13, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; (p) are SEQ ID NO: 2, SEQ ID NO: 26, SEQ ID NO: 42 and SEQ ID NO: 64, respectively; (q) are SEQ ID NO: 8, SEQ ID NO: 26, SEQ ID NO: 39 and SEQ ID NO: 64, respectively; (r) SEQ ID NO: 12, SEQ ID NO: 26, SEQ ID NO: 38 and SEQ ID NO: 64, respectively; (s) are SEQ ID NO: 14, SEQ ID NO: 28, SEQ ID NO: 43 and SEQ ID NO: 66, respectively; (t) SEQ ID NO: 15, SEQ ID NO: 26, SEQ ID NO: 41 and SEQ ID NO: 64, respectively; or (u) are SEQ ID NO: 16, SEQ ID NO: 29, SEQ ID NO: 44 and SEQ ID NO: 64, respectively.

5. The antibody of any one of claims 1-4, wherein the antibody comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 67-87.

6. The antibody of any one of claims 1-5, comprising a heavy chain variable region, wherein the heavy chain variable region comprises the amino acid sequence shown in any one of SEQ ID NOs: 67-87.

7. The antibody of any one of claims 1-6, wherein the gD protein is derived from a virus.

8. The antibody of claim 7, wherein the virus is herpes simplex virus (HSV).

9. The antibody of claim 8, wherein the HSV is HSV-1 or HSV-2.

10. The antibody of any one of claims 1-9, wherein the gD protein is a recombinant gD protein.

11. The antibody of any one of claims 1-10, wherein the antibody binds to HSV-1 and / or HSV-2.

12. The antibody of any one of claims 1-11, wherein the antibody has a K ranging from about 1 pM to about 1 μM. D Binds to the gD protein.

13. The antibody of any one of claims 1-12, wherein the K D The range is about 50 pM to about 4 nM.

14. The antibody of any one of claims 1-13, wherein the K D The range is 0.05nM to 0.2nM.

15. The antibody of any one of claims 1-14, wherein the antibody has a K of about 4 nM or less. D Binds to the gD protein.

16. The antibody of any one of claims 1-15, wherein the antibody is a single heavy domain antibody (sdAb) or a multispecific antibody.

17. The antibody of any one of claims 1-16, wherein the antibody is a neutralizing antibody.

18. The antibody of any one of claims 1-17, wherein the antibody is capable of neutralizing HSV-1 and / or HSV-2.

19. The antibody of any one of claims 17-18, wherein the antibody comprises an amino acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO:

85.

20. The antibody of any one of claims 1-16, wherein the antibody is a non-neutralizing antibody.

21. The antibody of any one of claims 1-16, wherein the antibody is a multispecific antibody comprising the amino acid sequence shown in SEQ ID NO: 85 and one or more amino acid sequences selected from SEQ ID NOs: 67-84 and 86-87.

22. A composition comprising the antibody of any one of claims 1-21.

23. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier.

24. A polynucleotide encoding the antibody of any one of claims 1-21.

25. A vector comprising the polynucleotide according to claim 24.

26. A cell capable of expressing the antibody of any one of claims 1-21.

27. A cell comprising the polynucleotide of claim 24 or the vector of claim 25.

28. A method of producing an antibody, comprising culturing the cell of claim 26 or 27, and recovering the antibody from the cell.

29. A method for treating HSV-1 and / or HSV-2 infection in a subject, comprising administering to the subject an effective amount of an antibody as described in any one of claims 1-21 or a composition as described in claim 22 or 23.

30. A method for detecting HSV-1 and / or HSV-2 in a sample, comprising contacting the sample with an antibody as described in any one of claims 1-21 or a composition as described in claim 22 or 23, and detecting the presence of the antibody.